Health Condition 1: null- Major depressive disorders with anxiety symptoms
Conditions
Interventions
Intervention1: desvenlafaxine tablet
: desvenlafaxine
tablet 50mg once daily for 8 weeks
Escitalopram 10 mg daily fro 8 weeks
Control Intervention1: escitalopram atblet: Escitalopram tablet 10 mg onc
Sponsors
Department of Pharmacology IPGMER Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: subjects of major depressive disorder with symptoms of anxiety with HAM score of seven to eighteen baseline HAMA score more than or equal to twelve Subjects must be willing to give written informed consent
Exclusion criteria
Exclusion criteria: subjects with age less tha eighteen or more than sixty Pregnant and lactating women Baseline HAMD score less than seven or more than eighteen Baseline HAMA score less than 12 Subjects with psychotic features Subjects with suicidality catatonic features Subjects on any antidepressant medications in the last two months Subjects with concurrent severe medical disorders like uncontrolled diabetes hypertension ischemic heart disease chronic renal failure cirrhosis any malignancy etc Subjects with history of substance abuse in the last two years Subjects with mixed depression and anxiety disorder or any other episodes of other mood disorder bipolar disorder dysthymia etc Subjects with any other psychiatric disorders Subjects on other concurrent medications known to have drug interact with the study medications like other SSRI SNRI tricyclic antidepressants etc Subjects with past history of anaphylaxis or hypersensitivity to any of the study medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes from baseline to study end of seventeen item HAMD depression rating scale changes from baselien to study end of HAM anxiety rating scaleTimepoint: Changes in HAMD 17 item score at baseline (day 0) and at study end (week 8) | — |
Secondary
| Measure | Time frame |
|---|---|
| Precentage of subjects achieving at least 50% reduction of baseline scores in HAMD 17 item percentage of subjects who have at least one Adverse Drug eventTimepoint: Baseline to study end -8 weeks | — |
Countries
India
Contacts
Public ContactDr Suparna Chatterjee
Associate Professor, Dept of Pharmacology, IPGMER, Kolkata
Outcome results
None listed